Memantine for Post-Operative Pain Control
Information source: University of Washington
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain, Post-operative
Intervention: Memantine (Drug); Placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Washington Official(s) and/or principal investigator(s):
Gregory Terman, MD, PhD, Principal Investigator, Affiliation: University of Washington Department of Anesthesiology and Pain Medicine
Overall contact:
Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu
Summary
Pain is a common element of surgery. Opiates (morphine, oxycodone, hydrocodone, methadone,
fentanyl) are very helpful in decreasing pain after surgery. Unfortunately, with repeated
use opiates lose their effectiveness, such that patients need to utilize more opiates to
achieve adequate pain relief - a phenomenon called tolerance. Sometimes tolerance to a pain
reliever's effects can develop in just a few hours. It is thought that activation of the
N-methyl d-aspartate (NMDA) receptor, a "switch" found on the surface of nerves, is
partially responsible for opiate tolerance. Memantine is a medication that limits the
activity of NMDA receptors in the brain and spinal cord. It has been used for years to help
patients with Alzheimer's Disease. In this study, we will study the effects of memantine
when combined with opiate medications to see whether it can increase the effectiveness of
opiates for pain after surgery and reduce the side effects caused by opiates (e. g.,
sedation, nausea, itching).
Clinical Details
Official title: Memantine for Post-Operative Pain Control
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change in numerical ratings on pain diaries as outpatients (pre and post surgery)Daily pain numerical ratings at rest and with movement as inpatients. Total opiate dose via patient controlled IV hydromorphone Oxycodone dose taken prn
Secondary outcome: Treatment group differences in side effects (nausea, itching, sedation, urinary retention following foley catheter discontinuation)Changes in cognitive function, assessed with Digit-Symbol Substitution Test and Trail Making Test B Changes in pain and quality of life questionnaire responses (SF-McGill-2, Brief Pain Questionnaire, SF-36 v2)
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Surgery for total hip replacement, knee replacement OR lumbar spinal fusion
- Taking no opiate medication OR taking opiate medication for at least 6 weeks
Exclusion Criteria:
- History of alcohol or drug abuse
- Clinical diagnosis of Alzheimer's Disease
- Prior adverse reaction to memantine
- Severe renal impairment (creatinine clearance <30 ml/min)
- Inability to give informed consent
Locations and Contacts
Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu
University of Washington Medical Center, Seattle, Washington 98195, United States; Recruiting
Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu
Additional Information
Related publications: Grande LA, O'Donnell BR, Fitzgibbon DR, Terman GW. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg. 2008 Oct;107(4):1380-3.
Starting date: January 2010
Last updated: June 25, 2010
|
